﻿<?xml version="1.0" encoding="utf-8"?><rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/"><channel><title>Cision News</title><link>https://news.cision.com</link><description>Cision is the leading global provider of media research, distribution, monitoring and evaluation services. With over 40 locations throughout the world, Cision provides the insight, expertise and intelligence that improve performance and build reputations.</description><pubDate>Tue, 09 Jun 2026 15:38:42 GMT</pubDate><image><title>Cision News</title><width>146</width><height>60</height><link>https://news.cision.com</link><url>https://news.cision.com/Content/img/news-logo.png</url></image><item><title>Dilaforette is granted SEK 2.85m for development of sevuparin for the treatment of severe malaria</title><link>http://news.cision.com/dilaforette-ab/r/dilaforette-is-granted-sek-2-85m-for-development-of-sevuparin-for-the-treatment-of-severe-malaria,c9329614</link><guid isPermaLink="false">cision1157511</guid><description><![CDATA[STOCKHOLM – November 2, 2012. Dilaforette announces today that it has been granted
SEK 2.85m from the Swedish Governmental Agency for Innovation Systems, Vinnova, for the development of sevuparin, a new potential treatment for severe malaria.
Sevuparin is intended as an adjunctive therapy to anti-parasite medicines in order to prevent the infected red blood cells from obstructing blood vessels and thereby reducing mortality. Each year nearly 10 million people are diagnosed with severe malaria and about one million die of the disease.

The grant from Vinnova will be used for process and]]></description><pubDate>Fri, 02 Nov 2012 07:00:00 GMT</pubDate></item></channel></rss>